Oncolys BioPharma, Inc. (4588) AI Stock Analysis

• Market Cap: ¥27.27B
• Dividend Yield: N/A
• Average Volume (3M): 1.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: -9.04%
• EPS Growth: 13.09%
• Country: JP
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -11.78
• Shares Outstanding: 28,299,600
• 10 Day Avg. Volume: 2,742,450
• 30 Day Avg. Volume: 1,517,566
• PEG Ratio: 0.23
• Price to Book (P/B): 4.11
• Price to Sales (P/S): 360.33
• P/FCF Ratio: -5.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: ¥1,030.00 ▲(1.48% Upside)

Oncolys BioPharma, Inc. has a low overall stock score primarily due to its poor financial performance, characterized by declining revenues and persistent losses. While technical analysis shows some positive momentum, the negative valuation metrics further weigh down the score. The lack of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Strong Equity Position

A strong equity position indicates solid capitalization, providing a buffer against financial instability and supporting future growth initiatives.

Innovative Cancer Therapies

The focus on innovative cancer therapies positions the company well within the growing immuno-oncology market, potentially leading to breakthrough treatments and partnerships.

Partnership Opportunities

Collaborations and licensing agreements with larger firms can provide essential funding and resources, accelerating development and commercialization efforts.

Negative Factors

Declining Revenues

Consistent revenue declines reflect challenges in product adoption and market penetration, potentially impacting long-term sustainability and growth.

Persistent Losses

Ongoing losses and negative margins highlight difficulties in achieving profitability, which could limit reinvestment in R&D and hinder competitive positioning.

Negative Cash Flow

Negative cash flow from operations suggests unsustainable business operations, necessitating external financing and posing risks to financial health.

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company Description

Oncolys BioPharma, Inc. (4588) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company is engaged in the research, development, and commercialization of biopharmaceuticals that harness the immune system to combat various types of tumors. Its core products include novel cancer therapies, particularly in the areas of immuno-oncology and targeted therapies, aimed at improving efficacy and safety for patients with cancer.

How the Company Makes Money

Oncolys BioPharma generates revenue primarily through the development and commercialization of its proprietary therapeutic products. This includes potential sales of its drugs post-approval, licensing agreements with larger pharmaceutical companies, and collaborations for joint development projects. The company may also receive milestone payments from partners as certain development and regulatory objectives are achieved. Significant partnerships with other biopharmaceutical firms can enhance its revenue streams, providing funding and shared resources for research and development efforts.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary

Oncolys BioPharma, Inc. faces serious financial challenges characterized by declining revenues, persistent losses, and negative cash flows. While the balance sheet shows strong equity, the overarching issue is the inability to achieve profitability and positive cash flow, posing risks to long-term viability.

Income Statement

Oncolys BioPharma, Inc. has experienced significant revenue decline, with a drop from 2022 to 2023 and further to 2024. The company has consistently operated at a loss, with negative EBIT and net income margins, reflecting challenges in scaling profitable operations.

Balance Sheet

The company maintains a healthy equity position with a strong equity ratio, indicative of solid capitalization. However, the continued losses affect return on equity negatively. While debt levels are manageable, the lack of profitability is concerning for long-term stability.

Cash Flow

Operating and free cash flow have remained negative, indicating ongoing operational cash burn. Despite positive financing cash flow, likely from fundraising, the inability to generate positive cash flow from operations is a critical risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.55M	31.38M	63.04M	976.18M	642.49M	314.18M
Gross Profit	27.68M	31.38M	30.61M	338.49M	198.80M	236.11M
EBITDA	-2.18B	-1.68B	-1.93B	-1.14B	-1.60B	-2.08B
Net Income	-2.24B	-1.68B	-1.94B	-1.15B	-1.62B	-2.10B
Balance Sheet
Total Assets	1.93B	3.20B	2.04B	2.65B	4.29B	2.80B
Cash, Cash Equivalents and Short-Term Investments	1.39B	2.41B	1.53B	1.71B	3.45B	2.07B
Total Debt	377.04M	324.64M	315.17M	393.66M	503.47M	525.08M
Total Liabilities	493.35M	446.65M	566.50M	491.69M	697.88M	793.09M
Stockholders Equity	1.44B	2.75B	1.47B	2.16B	3.59B	2.00B
Cash Flow
Free Cash Flow	0.00	-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
Operating Cash Flow	0.00	-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
Investing Cash Flow	0.00	-4.71M	-5.39M	20.12M	-942.00K	-37.58M
Financing Cash Flow	0.00	2.88B	1.14B	-113.83M	3.09B	242.26M

Oncolys BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1015.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 1015 is above the 20-day moving average (MA) of 972.40, above the 50-day MA of 805.96, and above the 200-day MA of 666.48, indicating a bullish trend. The MACD of 93.71 indicates Negative momentum. The RSI at 65.27 is Neutral, neither overbought nor oversold. The STOCH value of 87.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4579	58 Neutral	¥18.34B	―	―	―	9.87%	-24.41%
4880	55 Neutral	¥10.13B	-202.30	―	0.97%	-13.81%	-107.95%
4588	53 Neutral	¥27.27B	―	―	―	-9.04%	13.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4583	48 Neutral	¥8.71B	-8.16	―	―	25.28%	39.15%
4599	47 Neutral	¥16.96B	-8.77	―	―	―	5.58%
4888	45 Neutral	¥10.58B	-77.98	―	―	248.15%	76.92%

Oncolys BioPharma, Inc. Corporate Events

Oncolys BioPharma Reports Decline in Financial Performance for 2025

Oncolys BioPharma Inc. reported a decrease in net sales for the nine months ending September 30, 2025, with significant operating and ordinary losses compared to the previous year. The company’s financial position weakened, with a notable decline in total assets and net assets, reflecting ongoing challenges in its operations and market environment.

The most recent analyst rating on (JP:4588) stock is a Hold with a Yen726.00 price target. To see the full list of analyst forecasts on Oncolys BioPharma, Inc. stock, see the JP:4588 Stock Forecast page.